Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index | Links |
Title: |
Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria from the Refractory Headache Special Interest Section of the American Headache Society |
|||||||||||||
Certain migraines are labeled as refractory, but the entity lacks a
well-accepted operational definition. This article summarizes the results of a
survey sent to American Headache Society members to evaluate interest in a
definition for RM and what were considered necessary criteria. Review of the
literature, collaborative discussions and results of the survey contributed
to the proposed definition for RM. We also comment on our considerations in
formulating the criteria and any issues in making the criteria operational.
Headaches need to cause significant interference with function or quality of
life despite modification of triggers, lifestyle factors, and adequate trials
of acute and preventive medicines with established efficacy. Patients must
fail adequate trials of preventive medicines, alone or in combination, from
at least 2 of 4 drug classes including: beta-blockers, anticonvulsants,
tricyclics, and calcium channel blockers. Patients must also fail adequate
trials of abortive medicines, including both a triptan and dihydroergotamine
(DHE) and either nonsteroidal anti-inflammatory drugs (NSAIDs) or combination
analgesic, unless contraindicated. An adequate trial is defined as a period
of time during which an appropriate dose of medication is administered,
typically at least 2 months at optimal or maximum-tolerated dose, unless
terminated early due to adverse effects. The definition also employs
modifiers for the presence or absence of medication overuse, and with or
without significant disability.
Refractory Chronic Migraine:
|
Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index | Links
Copyright © 2002- Lawrence Robbins, MD
All Rights Reserved.
This site is maintained by MICE Training & Technology™ Web Design
Contact: